Produced By Or Extracted From Animal Tissue Patents (Class 514/21.92)
  • Patent number: 10969365
    Abstract: In one aspect, methods of biomolecular analysis are described herein. Briefly, a method comprises providing a composition comprising glycosaminoglycans and contacting the composition with a membrane comprising at least one nanopore. An electric field is applied across the nanopore, and data of glycosaminoglycan translocation events through the nanopore are recorded. A molecular weight distribution of the glycosaminoglycans is derived from the data.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: April 6, 2021
    Inventors: Adam R. Hall, Elaheh Rahbar, Paul DeAngelis
  • Patent number: 10471084
    Abstract: A composition and method for using it to prevent and/or relieve symptoms of acute respiratory tract infections, particularly bronchitis, in immune-compromised persons, particularly adults. The composition contains 2?-fucosyllactose and lacto-N-neotetraose and/or lacto-N-tetraose.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: November 12, 2019
    Assignee: Glycom A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs
  • Patent number: 10137198
    Abstract: A lipid layer forming composition comprises a volatile silicone oil of a boiling point above 180° C., a polar lipid, optionally a C2-C4 aliphatic alcohol, optionally a pharmacologically or cosmetically active agent or a protective agent. The lipid layer forming composition can be applied to a biological surface by spraying, dipping or brushing to form a stable polar lipid layer on the surface.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: November 27, 2018
    Assignee: LIPIDOR AB
    Inventors: Anders Carlsson, Jan Holmback
  • Patent number: 9884119
    Abstract: A lipid layer forming composition comprises a volatile silicone oil of a boiling point above 180° C., a polar lipid, optionally a C2-C4 aliphatic alcohol, optionally a pharmacologically or cosmetically active agent or a protective agent. The lipid layer forming composition can be applied to a biological surface by spraying, dipping or brushing to form a stable polar lipid layer on the surface.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: February 6, 2018
    Assignee: LIPIDOR AB
    Inventors: Anders Carlsson, Jan Holmback
  • Patent number: 9801946
    Abstract: Embodiments of the present inventions comprise composites of polyurethane(s), osteoconductive matrix, and, optionally, a growth factor. Embodiments further comprise methods of making such composite and uses thereof. The osteoconductive matrix can be a tricalcium phosphate, bioglass, or the like, and can include particles that are surface modified. Growth factors can be provided in powder form, including bone morphogenic proteins such as rhBMP-2. A composition may be moldable and/or injectable. After implantation or injection, a composition may be set to form a porous composite that provides mechanical strength and supports the in-growth of cells.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: October 31, 2017
    Assignee: Vanderbilt University
    Inventors: Scott A. Guelcher, Jerald Dumas, Edna M. Prieto, Anne Talley, Andrew Harmata, Katarzyna Zienkiewicz
  • Patent number: 9168235
    Abstract: An aqueous patch containing diclofenac sodium, wherein the patch contains a homogeneous mixed solution of diclofenac sodium, wherein the solution is obtained by mixing crotamiton, diclofenac sodium and water in the mixture ratio of crotamiton/diclofenac sodium of 8.0 or less and the mixture ratio of (water+crotamiton)/diclofenac sodium of 3.0-20.0.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: October 27, 2015
    Assignee: Teikoku Seiyaku Co., Ltd.
    Inventors: Takashi Kamakura, Kazuha Tani, Yuichiro Mabuchi, Kazuhito Okada
  • Publication number: 20150119343
    Abstract: A method of producing a protein or polypeptide, such as, for example, TSG-6 protein, or a biologically active fragment, derivative or analogue thereof, by introducing into mammalian cells a polynucleotide encoding the biologically active protein or polypeptide or biologically active fragment, derivative, or analogue thereof. The cells then are suspended in a protein-free medium that includes at least one agent that suppresses production of hyaluronic acid, hyaluronan, or a salt thereof by the cells. The cells are cultured for a time sufficient to express the biologically active protein or polypeptide or biologically active fragment, derivative or analogue thereof. The biologically active protein or polypeptide, or fragment, derivative, or analogue thereof then is recovered from the cells, such as, for example, by recovering the protein or polypeptide secreted by the cells from the cell culture medium.
    Type: Application
    Filed: November 1, 2012
    Publication date: April 30, 2015
    Inventors: Darwin J. Prockop, Jun Watanabe, Dong-Ki Kim, RyangHwa Lee, Hosoon Choi
  • Patent number: 8980833
    Abstract: The present invention relates to novel cytotoxic molecules and their use for the treatment of cancer and other diseases.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: March 17, 2015
    Assignee: R&D-Biopharmaceuticals GmbH
    Inventor: Wolfgang Richter
  • Patent number: 8921310
    Abstract: The present invention relates to an agent for improving lipid metabolism, a food/drink, and a feed, containing ?s-casein as an active ingredient thereof. In addition, the present invention relates to an agent for suppressing body weight gain, an agent for reducing body fat, and an agent for reducing blood lipid, containing the agent for improving lipid metabolism.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: December 30, 2014
    Assignee: Morinaga Milk Industry Co., Ltd.
    Inventors: Yuuki Somoto, Masayuki Ikeda
  • Publication number: 20140271886
    Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: pSivida Corp
    Inventors: Christian Barnett, Paul Ashton, Leigh T. Canham
  • Patent number: 8829166
    Abstract: A method for purifying bone-derived osteoinductive proteins including a demineralization process, a protein extraction process, a high molecular weight ultrafiltration process, a low molecular weight ultrafiltration process, and a recover process. The high and low ultrafiltration processes preferably select proteins having a nominal molecular weight between approximately 8 kilodaltons and approximately 100 kilodaltons. Processes of the present invention may be used to recover osteoinductive proteins from bone demineralization waste streams.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: September 9, 2014
    Assignee: Zimmer Orthobiologics, Inc.
    Inventors: Kevin Thorne, Rama Akella
  • Patent number: 8828417
    Abstract: For an implantable device intended for use in the human body an in-vivo colonization with autologous cells is often desired. The devices, especially prosthetic devices like implant tissues, grafts, shunts, vessels, organs or a part of organs are commonly derived from animal or human origin and comprise a collagen-based tissue matrix. The invention proposes a coating deposited on a surface of the device and comprising the matrix protein CCN1 as an extracellular matrix-associated protein mediating cell adhesion or cell migration.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: September 9, 2014
    Assignee: Corlife OHG
    Inventors: Andres Hilfiker, Denise Hilfiker-Kleiner, Artur Lichtenberg
  • Patent number: 8771752
    Abstract: A composition for preventing and treating fatty liver is disclosed. The composition includes a lactoferrin and a trivalent chromium compound. The trivalent chromium compound of the present invention is selected from the group consisting of chromium (III) chloride hexahydrate, chromium (III) chloride, chromium (III) acetate, chromium (III) sulfate, chromium picolinate, chromium nicotinate, chromium GTF, chromium yeast extract, other inorganic salts of trivalent chromium, other organic salts of trivalent chromium, and combinations thereof. The composition of the present invention can provide a beneficial effect in preventing and treating fatty liver by effectively reducing multiple risk factors of fatty liver disease.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: July 8, 2014
    Assignee: National Chung Hsing University
    Inventors: Frank Chiahung Mao, Wen-Ying Chen
  • Publication number: 20140171378
    Abstract: Disclosed are compositions comprising isolated peptides having a leucine content of from about 12 to about 40 weight percent. Also disclosed is a method for isolating leucine-rich peptides from protein sources such as bovine whey and methods of use for these peptides to provide beneficial effects in a human and/or animal such as increasing blood flow, decreasing blood pressure, increasing muscle mass, improving cognitive function, improving cardiovascular function, etc.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Inventors: Brent Petersen, Loren S. Ward, Eric D. Bastian, Stanley Wrobel
  • Patent number: 8748656
    Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: June 10, 2014
    Assignee: BHI Limited Partnership
    Inventors: Xianqi Kong, Mohamed Atfani, Benoit Bachand, Abderrahim Bouzide, Stéphane Ciblat, Sophie Levesque, David Migneault, Isabelle Valade, Xinfu Wu, Daniel Delorme
  • Patent number: 8716244
    Abstract: The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: May 6, 2014
    Assignee: Sciotec Diagnostic Technologies GmbH
    Inventors: Albert Missbichler, Franz Gabor, Herwig Reichl
  • Patent number: 8715654
    Abstract: The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: May 6, 2014
    Assignee: Celtaxsys, Inc.
    Inventors: Surendra Chavan, Jonathan L. Moon, Lopa Bhatt
  • Publication number: 20140072536
    Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 13, 2014
    Applicant: Board of Regents of the Nevada System of Higher Education On Behalf of the University of Nevada
    Inventors: Ryan Wuebbles, Dean Burkin
  • Publication number: 20130288972
    Abstract: Methods for reducing the severity of an arthritic condition or repairing an osteochondral defect are carried out by administering to a subject compositions comprising a member of the matrilin family of proteins, e.g., a matrilin protein, fragment thereof, or nucleic acid encoding the protein or fragment.
    Type: Application
    Filed: January 5, 2012
    Publication date: October 31, 2013
    Inventors: Qian Chen, Chathuraka T. Jayasuriya
  • Patent number: 8563045
    Abstract: Hydrolyzed collagen type II powder compositions for inducing cartilage formation in an individual, method of preparing the compositions and use of the compositions in treating connective tissue disorder, replenishing skin viscoelasticity. The compositions are administered through an orally ingestible delivery medium for absorption into the gastrointestinal tract. The compositions are administered through a topical delivery medium for absorption into a dermis of the individual.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: October 22, 2013
    Assignee: Biocell Technology, LLC
    Inventor: Suhail Ishaq
  • Patent number: 8545893
    Abstract: Provided herein are keratin compositions useful for treating ischemia and/or reperfusion injury, such as that associated with myocardial infarct, ischemic stroke, brain trauma such as traumatic brain injury, hypothermia, chronic wounds, and burns.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: October 1, 2013
    Assignee: Wake Forest University Health Sciences
    Inventors: Mark E. Van Dyke, Thomas L. Smith, Michael Callahan, Luke Burnett
  • Patent number: 8530417
    Abstract: The present invention relates to granulocyte colony stimulating factor (G-CSF) modified with Y-shaped branched polyethylene glycol (YPEG-G-CSF) at a specific lysine (Lys 17) and the preparation thereof, as well as the pharmaceutical composition comprising YPEG-G-CSF and use thereof.
    Type: Grant
    Filed: December 29, 2007
    Date of Patent: September 10, 2013
    Assignee: Biosteed Gene Expression Tech Co. Ltd.
    Inventors: Shiyuan Wang, Jianhua Zheng, Li Sun, Huili Cai, Meihua Yang, Yan He, Ping Chen, Hongyuan Deng, Liping Zhong, Shuying Huang
  • Patent number: 8519098
    Abstract: An ionic complex precipitate comprising a hedgehog protein and deoxycholate whereby the forming of the complex does not enhance the solubility of said protein, is suitable for increasing the activity of the protein and/or for the delayed release of the protein.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: August 27, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Apollon Papadimitriou
  • Publication number: 20130216505
    Abstract: Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.
    Type: Application
    Filed: December 31, 2012
    Publication date: August 22, 2013
    Inventor: Amit Patel
  • Publication number: 20130165393
    Abstract: A new method for krill meal production has been developed using a two step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum. In the second stage the krill without phospholipids are cooked. Following this, residual fat and astaxanthin are removed from the krill using mechanical separation methods. A novel krill meal product with superior nutritional and technical properties is prepared.
    Type: Application
    Filed: January 23, 2013
    Publication date: June 27, 2013
    Inventors: Snorre Tilseth, Nils Hoem
  • Patent number: 8445026
    Abstract: Novel methods for biological effective, stable amorphous and monoclinic selenium nanoparticles are disclosed. They are prepared by reacting selenium source with a reducing agent or an oxidative agent in an aqueous media at a temperature between 0-100° C. in the presence of selenium binding polymer molecules such as poly/oligopeptide acids or peptone or nucleic acids or poly/oligosaccharide or their mixtures.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: May 21, 2013
    Inventors: Xueyun Gao, Yi Sun
  • Patent number: 8445232
    Abstract: Prepared is an extract composition having an improved protein synthetic activity in a cell-free protein synthesis system using a mammalian cultured cell extract. An eukaryotic translation initiation factor and/or translational regulator are added to a cell-free protein synthesis system comprising an extract prepared from cultured mammalian cells and a template mRNA. These factors are one or more selected from the group consisting of eukaryotic translation initiation factors 4E (eIF4E), 2 (eIF2) and 2B (eIF2B), and eukaryotic translational regulator p97.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: May 21, 2013
    Assignee: Riken
    Inventors: Hiroaki Imataka, Satoshi Mikami, Shigeyuki Yokoyama
  • Publication number: 20130121969
    Abstract: The present invention relates to biocompatible, biodegradable polyurethane/urea polymeric compositions that are capable of in-vivo curing with low heat generation to form materials suitable for use in scaffolds in tissue engineering applications such as bone and cartilage repair. The polymers are desirably flowable and injectable and can support living biological components to aid in the healing process. They may be cured ex-vivo for invasive surgical repair methods, or alternatively utilized for relatively non-invasive surgical repair methods such as by arthroscope. The invention also relates to prepolymers useful in the preparation of the polymeric compositions, and to methods of treatment of damaged tissue using the polymers of the invention.
    Type: Application
    Filed: October 31, 2012
    Publication date: May 16, 2013
    Inventors: Raju Adhikari, Pathiraja Arachchillage Gunatillake
  • Patent number: 8420605
    Abstract: Hydrogel compositions comprise an aqueous dispersion phase and a plurality of peptides, or derivatives, or analogues thereof. Each peptide comprises at least two amino acid residues and an aromatic stacking ligand and the hydrogel is formed by self-assembly of said peptides in said aqueous dispersion medium. The aqueous dispersion phase is physiologically acceptable and may have a pH of 6 to 8, as may the hydrogel itself. The hydrogel may be used for cell culture or for treatment of medical conditions characterized by tissue loss/damage.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: April 16, 2013
    Assignee: The University of Strathclyde
    Inventors: Rein Vincent Ulijn, Vineetha Jayawarna, Andrew Smith, Julie Elizabeth Gough
  • Patent number: 8409605
    Abstract: A kit for forming a biocompatible material provides a protein solution and a polymer solution including a derivative of a hydrophilic polymer with a functionality of at least three. Upon mixing. the protein solution and the polymer solution cross-link to form a non-liquid, three-dimensional network that degrades over time back to a liquid form. The polymer includes a degradation control region selected to achieve a desired degradation period and a cross-linking group selected to achieve a desired cross-linking period. The kit provides instructions for forming a mixture of the protein solution and polymer solution and for applying the mixture. The mixture serves as the foundation for multiple material composition species, each adapted to a specific therapeutic indication.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: April 2, 2013
    Assignee: Neomend, Inc.
    Inventors: Olexander Hnojewyj, Charles F. Milo, Gregory M Cruise
  • Patent number: 8399014
    Abstract: To provide a method of reducing an intrinsic harsh/astringent taste of protamine and a protamine salt and effectively using a fat absorption suppressive effect of these. A complex is formed by reacting at least one of acidic macromolecular substances, such as alginate and polyglutamate, and gum arabic which are capable of forming a complex reducing harsh/astringent taste and dissociating protamine having a lipase inhibitory activity by pepsin treatment, with protamine or a protamine salt.
    Type: Grant
    Filed: December 24, 2009
    Date of Patent: March 19, 2013
    Assignee: Maruha Nichiro Foods, Inc.
    Inventor: Yoshinori Takahashi
  • Patent number: 8383144
    Abstract: A method mixes a first component, a second component, and a buffer material. The first component includes an electrophilic polymer material comprising poly(ethylene glycol) having a functionality of at least three. The second component includes a nucleophilic material comprising a natural or synthetic protein at a concentration of about 25% or less that, when mixed with the first component within a reaction pH range, cross-links with the first component to form a non-liquid, three-dimensional barrier. The buffer material includes tris-hydroxymethylaminomethane having a pH within the reaction pH range. The method applies the mixture to adhere to a tissue region.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: February 26, 2013
    Assignee: Neomend, Inc.
    Inventor: Olexander Hnojewyj
  • Patent number: 8378072
    Abstract: The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the modulation of unwanted immune responses, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: February 19, 2013
    Assignee: Declion Pharmaceuticals, Inc.
    Inventor: Dustan Bonnin
  • Patent number: 8372812
    Abstract: A new method for krill meal production has been developed using a two step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum. In the second stage the krill without phospholipids are cooked. Following this, residual fat and astaxanthin are removed from the krill using mechanical separation methods. A novel krill meal product with superior nutritional and technical properties is prepared.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: February 12, 2013
    Assignee: Aker Biomarine ASA
    Inventors: Snorre Tilseth, Nils Hoem
  • Publication number: 20130012449
    Abstract: The invention discloses a new solvent-free process for obtaining phospholipids and neutral lipids enriched krill oils containing DHA and EPA poly-unsaturated fatty acids and astaxanthin. The process includes cooking fresh krill at high temperature-without agitation and or grinding; decanting the cooked krill for obtaining a partial de-fatted and de-watered solid and a liquid; squeezing the obtained solid to obtain a press liquid and a solid fraction; centrifuging the press liquid to obtain the phospholipids enriched krill oil; centrifuging of the decanter liquid obtained to obtain the neutral lipid enriched krill oil and stickwater.
    Type: Application
    Filed: October 30, 2009
    Publication date: January 10, 2013
    Applicant: THAROS LTD.
    Inventors: Dimitri Sclabos Katevas, Raul R. Toro Guerra, Mario M. Chiong Lay
  • Publication number: 20120315234
    Abstract: The inventive compositions comprise in a deionized water base, a composition comprising: a preservative, a chelating agent; one or more moisturizer and hydrolyzed keratin protein; an antioxidant selected from the group consisting of citric acid and a vitamin E salt; and an emulsifier-water trap selected from the group consisting of cetearyl alcohol and glyceryl stearate; and PEG-40 castor oil. The composition, which is in liquid form, may be applied in the form of a spray or mist by dipping the affected area in the liquid or by pouring a small amount of the liquid onto the hair or body to be treated.
    Type: Application
    Filed: June 25, 2012
    Publication date: December 13, 2012
    Applicant: Eqyss Grooming Products
    Inventors: Don Van, Dallas Van Kempen
  • Publication number: 20120309697
    Abstract: Methods of diagnosing or prognosing a disease or condition associated with increased or over expression of macrophage inhibitory cytokine-1 (MIC-1) are disclosed. The methods typically involve detecting a change in the amount of MIC-1 in a test body sample from a subject taken at two or more timing points. The change in the amount of MIC-1 may be adjusted for the effect of at least the following factors as appropriate: the gender of the subject, the age of the subject, the body mass index (BMI) of the subject, the subject being a smoker, the subject being a user of NSAIDs, and the waist-to-hip ratio where the subject is female. The methods are particularly suitable for diagnosing or prognosing the presence of one or more colorectal polyp(s).
    Type: Application
    Filed: October 27, 2010
    Publication date: December 6, 2012
    Inventors: Samuel Norbert Breit, David Alexander Brown, Kenneth W. Hance, Elaine Lanza, Connie J. Rogers
  • Publication number: 20120309685
    Abstract: Pharmaceutical, dental and/or cosmetic composition consisting of purified Enamel Matrix Derivative (EMD) proteins which have a molecular weight between 1 and 55 kDa, formulated in a suitable pharmaceutical carrier. The composition is depleted of proteins which have a molecular weight between 56 and 160 kDa and an iso-electric point between 3-10. The purified Enamel Matrix Derivative (EMD) proteins are depleted of proteinase inhibitors, such as ?1-antichymotrypsin and/or Fetuin A. The composition is preferably used for promoting and/or inducing regeneration of hard tissue, tissue mineralization, bone growth and/or bone regrowth, regeneration of dentin, cementogenesis, and/or binding between parts of living mineralized tissue, for bonding of a piece of living mineralized tissue to a bonding site on a piece of other living tissue, for endorsing binding between hard tissues, and/or for filling a mineralized wound cavity and/or tissue defect following from a procedure and/or trauma.
    Type: Application
    Filed: October 29, 2010
    Publication date: December 6, 2012
    Applicant: Straumann Holding AG
    Inventors: P. Mark Bartold, Peter S. Zilm, Corinna Mauth, Ruzica Ranevski
  • Patent number: 8324167
    Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: December 4, 2012
    Assignee: DMI Biosciences, Inc.
    Inventors: David Bar-Or, Raphael Bar-Or, Richard Shimonkevitz
  • Patent number: 8314059
    Abstract: The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: November 20, 2012
    Assignee: FibroGen, Inc.
    Inventors: Allan Flyvbjerg, Guangjie Guo, David Y. Liu, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang
  • Publication number: 20120264699
    Abstract: A method of producing blood serum containing prophylactically or therapeutically active proteins, including obtaining blood from a patient, incubating the blood at a suitable temperature to induce production of prophylactically or therapeutically active proteins, and removing the prophylactically or therapeutically active proteins from the blood.
    Type: Application
    Filed: June 25, 2012
    Publication date: October 18, 2012
    Inventors: Reinhold Schmieding, David O. Shepard
  • Publication number: 20120251591
    Abstract: Compositions and methods for delivering bioactive agents, such as vitamins, hormones, nutrients and drugs, by stabilizing and or solubilizing these agents in a polymer matrix. The carrier polymers can be used in drug delivery and are useful for delivery of small molecules.
    Type: Application
    Filed: April 19, 2012
    Publication date: October 4, 2012
    Applicant: Polytechnic Institute of New York University
    Inventors: Jin Kim Montclare, Man Xia Lee, Jennifer Haghpanah
  • Patent number: 8278046
    Abstract: The disclosure is related generally to methods for testing mammary fluid (including milk) to establish or confirm the identity of the donor of the mammary fluid. Such methods are useful in the milk-bank business to improve safety.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: October 2, 2012
    Assignee: Prolacta Bioscience
    Inventors: Elena M. Medo, Martin L. Lee, David J. Rechtman
  • Publication number: 20120230950
    Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.
    Type: Application
    Filed: May 21, 2012
    Publication date: September 13, 2012
    Applicant: Humacyte, Inc.
    Inventors: Laura Niklason, Yuling Li, Juliana Blum, Shannon Dahl, Geoffrey Erickson, Frank Zeigler
  • Publication number: 20120208767
    Abstract: A method includes obtaining a biological sample from a subject that does not display a symptom of Painful Bladder Syndrome (PBS). The method also includes analyzing the biological sample for a mutated form of NAD(P)H dehydrogenase [quinone], also known as Quinone Oxidoreductase 1, abbreviated NQO1, or a mutation of a NQO1 gene. The method also includes determining a risk of PBS for the subject based on analyzing the biological sample. In some methods, the mutation determined to present an increased risk is a cytosine to thymine nucleotide substitution at a position that leads to a proline to serine amino acid substitution at amino acid position 187 to produce a protein NQO1P187S. Another method includes selecting a subject that has above normal risk of Painful Bladder Syndrome (PBS) or is expressing a symptom of PBS, and treating the subject with a therapeutically effective amount of an antioxidant.
    Type: Application
    Filed: February 14, 2012
    Publication date: August 16, 2012
    Applicant: University of Maryland, Baltimore
    Inventor: Anil K. Jaiswal
  • Publication number: 20120183548
    Abstract: Methods of treatment using IL-27 antagonists are provided. Such methods include, but are not limited to, methods of treating steroid-resistant conditions, such as asthma, chronic obstructive pulmonary disease (COPD), systemic lupus erythematosus (SLE), and inflammatory bowel disease. Such antagonists include, but are not limited to, antibodies that bind IL-27 and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to its receptor); antibodies that bind the IL-27 receptor, alpha subunit, and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to the receptor); and soluble forms of IL-27RA.
    Type: Application
    Filed: January 13, 2012
    Publication date: July 19, 2012
    Inventors: Brian Wong, Jennifa Gosling
  • Publication number: 20120171190
    Abstract: Methods for diagnosing chronic diarrhea and other gastrointestinal conditions. In the methods, a sample of gastrointestinal secretions is obtained from a control group; or a group who has been diagnosed with either healthy gastrointestinal tracts or with a gastrointestinal condition, like chronic diarrhea. The control group samples are analyzed in any suitable manner to determine the levels of gastrointestinal secretions, including one or more autophagy-related proteins, cytokeratins, digestive enzymes, or other proteins. The results of the sample analysis are used to create a database containing profiles of normal and abnormal gastrointestinal secretions. As the database is created and specific secretion level abnormalities are identified, patients may be diagnosed with these abnormalities and be treated by adjusting the levels of specific secretions.
    Type: Application
    Filed: March 7, 2012
    Publication date: July 5, 2012
    Inventor: Thomas M. Donndelinger
  • Publication number: 20120172319
    Abstract: Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.
    Type: Application
    Filed: December 22, 2011
    Publication date: July 5, 2012
    Inventors: JoMay Chow, Steven R. Davis, Rachael Buck, Geralyn O. Duska-McEwen, Hawley K. Linke
  • Publication number: 20120157381
    Abstract: The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions.
    Type: Application
    Filed: August 29, 2011
    Publication date: June 21, 2012
    Applicant: The University of Vermont and State Agriculture College
    Inventor: Jeffrey Spees
  • Publication number: 20120083458
    Abstract: The invention features methods of diagnosing inflammatory disease based on the elevated presence microparticles (MP) expressing certain receptors. The invention also features methods of decreasing fibrosis in the liver by administering MP to subjects with liver fibrosis.
    Type: Application
    Filed: September 20, 2011
    Publication date: April 5, 2012
    Inventors: Detlef Schuppan, Yury Popov, Miroslaw Kornek